Ambu gets US approval for new product

Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021

Photo: Andrew Kelly/REUTERS / X02844

The US Food and Drug Administration (FDA) has approved Ambu's product Vivasight 2 DLT, a ventilation tube with a camera, for single-use purposes.

The medtech company revealed the news in connection with its Q2 report released on Wednesday morning.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs